Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma

Basit Öğe Kaydı
dc.contributor.authorYildirim, Z
dc.contributor.authorOzlu, T
dc.contributor.authorBulbul, Y
dc.contributor.authorBayram, H
dc.date.accessioned2024-04-24T17:11:33Z
dc.date.available2024-04-24T17:11:33Z
dc.date.issued2004
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Although current guidelines suggest the use of inhaled corticosteroids as the first line therapy in persistent asthma, the concerns about high-dose corticosteroids may limit their usage. We aimed to investigate the efficacy of inhaled budesonide plus oral montelukast versus a double dose of inhaled budesonide. Methodology: Thirty patients with moderate asthma took part in the study. Following a 2-week run in period, the patients were randomized into two groups to receive 400 mug/day of inhaled budesonide plus 10 mg/day of montelukast (BUD + M group) or 800 mug/day of inhaled budesonide (high BUD group). The patients were evaluated at 2-week intervals (during a total treatment period of 6 weeks) for symptom scores, asthma exacerbations, lung function, use of short-acting beta(2) agonist, blood eosinophil counts and adverse events. Results: At the end of the study, morning and daytime symptom scores were significantly reduced within the groups. Although there was a significant decrease in the frequency of short-acting beta(2) agonist use in the BUD + M group, the decrease in the high BUD group was not significant. During the study period, no patient in either group experienced an asthma exacerbation. Blood eosinophil levels significantly declined in both the BUD + M (0.87 +/- 0.31%) and high BUD groups (0.67 +/- 0.29%) as compared with baseline levels (BUD + M = 2.60 +/- 0.65%, high BUD group = 2.60 +/- 0.47%; P < 0.05). Conclusion: Our results suggest that the addition of montelukast to low-dose inhaled budesonide is as effective as a double dose of inhaled budesonide in asthma control.en_US
dc.identifier.doi10.1111/j.1440-1843.2004.00555.x
dc.identifier.endpage248en_US
dc.identifier.issn1323-7799
dc.identifier.issn1440-1843
dc.identifier.issue2en_US
dc.identifier.pmid15182276
dc.identifier.scopus2-s2.0-3142672720
dc.identifier.scopusqualityQ1
dc.identifier.startpage243en_US
dc.identifier.urihttps://doi.org/10.1111/j.1440-1843.2004.00555.x
dc.identifier.urihttps://hdl.handle.net/11468/17592
dc.identifier.volume9en_US
dc.identifier.wosWOS:000224630500015
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofRespirology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAsthma Treatmenten_US
dc.subjectBudesonideen_US
dc.subjectLeukotriene Receptor Antagonisten_US
dc.subjectModerate Asthmaen_US
dc.subjectMontelukasten_US
dc.titleAddition of montelukast versus double dose of inhaled budesonide in moderate persistent asthmaen_US
dc.titleAddition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu